Alopecia areata

Kirsten Rønholt; Stine Simonsen; Farnam Barati Sedeh; Lone Skov

Alopecia areata

Kirsten Rønholt, Stine Simonsen, Farnam Barati Sedeh, Lone Skov

Dermatologisk Afdeling

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Alopecia areata (AA) is an autoimmune disease where inflammation around the lowest part of the hair follicle results in non-scarring hair loss. This review investigates the course of the disease, its unpredictability and variation from a single patch of scalp hair loss to the loss of all hair on the body. The first drug with AA indication was approved in 2022, the JAK-inhibitor baricitinib. This paves the way for future research that may lead to the development of new effective pathogenesis-specific treatments.

Bidragets oversatte titel	Alopecia areata
Originalsprog	Dansk
Artikelnummer	V07230456
Antal sider	10
Tidsskrift	Ugeskrift for Laeger
Vol/bind	185
Udgave nummer	47
Status	Udgivet - 20 nov. 2023

Emneord

Alopecia
Alopecia Areata/drug therapy
Autoimmune Diseases
Humans
Janus Kinase Inhibitors

Adgang til dokumentet

https://ugeskriftet.dk/videnskab/alopecia-areata

Citationsformater

@article{eab5c25689c6480382f227b8b1fd31dc,

title = "Alopecia areata",

abstract = "Alopecia areata (AA) is an autoimmune disease where inflammation around the lowest part of the hair follicle results in non-scarring hair loss. This review investigates the course of the disease, its unpredictability and variation from a single patch of scalp hair loss to the loss of all hair on the body. The first drug with AA indication was approved in 2022, the JAK-inhibitor baricitinib. This paves the way for future research that may lead to the development of new effective pathogenesis-specific treatments.",

keywords = "Alopecia, Alopecia Areata/drug therapy, Autoimmune Diseases, Humans, Janus Kinase Inhibitors",

author = "Kirsten R{\o}nholt and Stine Simonsen and {Barati Sedeh}, Farnam and Lone Skov",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2023",

month = nov,

day = "20",

language = "Dansk",

volume = "185",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "47",

}

TY - JOUR

T1 - Alopecia areata

AU - Rønholt, Kirsten

AU - Simonsen, Stine

AU - Barati Sedeh, Farnam

AU - Skov, Lone

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2023/11/20

Y1 - 2023/11/20

N2 - Alopecia areata (AA) is an autoimmune disease where inflammation around the lowest part of the hair follicle results in non-scarring hair loss. This review investigates the course of the disease, its unpredictability and variation from a single patch of scalp hair loss to the loss of all hair on the body. The first drug with AA indication was approved in 2022, the JAK-inhibitor baricitinib. This paves the way for future research that may lead to the development of new effective pathogenesis-specific treatments.

AB - Alopecia areata (AA) is an autoimmune disease where inflammation around the lowest part of the hair follicle results in non-scarring hair loss. This review investigates the course of the disease, its unpredictability and variation from a single patch of scalp hair loss to the loss of all hair on the body. The first drug with AA indication was approved in 2022, the JAK-inhibitor baricitinib. This paves the way for future research that may lead to the development of new effective pathogenesis-specific treatments.

KW - Alopecia

KW - Alopecia Areata/drug therapy

KW - Autoimmune Diseases

KW - Humans

KW - Janus Kinase Inhibitors

M3 - Review

C2 - 38018739

SN - 0041-5782

VL - 185

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 47

M1 - V07230456

ER -

Alopecia areata

Abstract

Emneord

Adgang til dokumentet

Fingeraftryk

Citationsformater